Imunon, Inc.
CLSN
株式のランク
#34855
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
株価
$1.96
最終同期: 2022-09-20
時価総額
$4.46M
変化（1日）
0.00%
変化（1年）
122.70%
国
US
取引 Imunon, Inc. (CLSN)
カテゴリー
Healthcare
Imunon, Inc.（CLSN）の株価履歴
終値の最高値: $0.93 （2025-01-01）
終値の最安値: $37.95 （2018-01-01）
終値の最安値: $37.95 （2018-01-01）
Imunon, Inc. の株価履歴（2018 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2025 | 10.76% |
| 2024 | -3.79% |
| 2023 | -36.24% |
| 2022 | -86.26% |
| 2021 | -10.52% |
| 2020 | -70.48% |
| 2018 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $536.87 | 25.89% |
US
|
|
| $191.60 | 613.60% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $884.30 | 8.61% |
NL
|
